Bortezomib

Product name: Bortezomib

CAS NO.: 179324-69-7

MF: C19H25BN4O4

MW: 384.24

Bortezomib is an injection. Bortezomib is a reversible inhibitor of the chymase-like activity of 26S protease in mammalian cells. In vitro tests demonstrated that bortezomib is cytotoxic to many types of cancer cells. Preclinical tumor models In vivo testing demonstrates that bortezomib delays tumor growth, including multiple myeloma. This product is used in the treatment of patients with multiple myeloma, the effectiveness is based on its efficiency.

 Function & Application:

Multiple myeloma:

This product can be used for the treatment of patients with multiple myeloma who have not been treated before and are not suitable for high-dose chemotherapy and bone marrow suppression.Or single drug for at least one or more patients with multiple myeloma recurrence after treatment.

Cell lymphoma:

This product can be used for the treatment of patients with recurrent or refractory cell lymphoma. This patient has received at least one treatment before using this product.Indications for the security effectiveness of the data from a study of abroad always relapse after treatment set of cell lymphoma one-armed Ⅱ period clinical research (see "clinical trials"),